Physician

Amanda Lynn Gillespie-Twardy, M.D.

According to 2025 Medicare claims, Amanda Gillespie-Twardy, M.D. (NPI: 1417140559) practices hematology/oncology in the Roanoke, VA market, with the plurality of this provider's patient population coming from Roanoke City, VA. This provider's primary affiliated billing organization is ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (NPI: 1487621496; TIN: 541922084) and primary practice location at 24014-2419.

Gillespie-Twardy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 683 traditional Medicare patients, billed 135,099 HCPCS/CPT codes, and received $3,091,346 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,473 prescription claims across 275 beneficiaries totaling $3,747,370 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 88 claims. Open Payments data shows 870 records totaling $1,512,235. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,161,685 to $3,091,346. Similarly, Part D prescription costs have risen steadily, from $102,164 to $3,747,370. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	539	100,461	$1,161,685
2016	416	55,566	$796,692
2017	634	88,056	$1,725,729
2018	623	129,446	$1,830,765
2019	687	165,130	$2,694,931
2020	751	223,492	$3,499,668
2021	681	193,812	$3,213,809
2022	756	186,626	$2,998,138
2023	754	206,040	$3,720,102
2024	683	135,099	$3,091,346

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	67	288	$102,164
2016	57	449	$147,902
2017	123	680	$397,267
2018	137	885	$1,364,779
2019	172	964	$1,817,345
2020	196	1,392	$2,304,765
2021	237	1,518	$2,901,663
2022	229	1,351	$2,680,284
2023	236	1,230	$2,594,484
2024	275	1,473	$3,747,370

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	40	$3,474
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	25	$2,454
2019	60	161	$13,739
2020	47	146	$10,826
2021	42	161	$9,723
2022	60	152	$4,801
2023	12	41	$8,631
2024	28	88	$2,673

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	239	525	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	180	210	$55
80053	Blood test, comprehensive group of blood chemicals	265	949	$10
36415	Insertion of needle into vein for collection of blood sample	261	666	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	327	1,316	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	50	1,500	$724,034
Jakafi	Ruxolitinib Phosphate	26	773	$456,389
Ibrance	Palbociclib	28	784	$430,533
Cabometyx	Cabozantinib S-Malate	15	450	$375,828
Lenalidomide	Lenalidomide	17	427	$204,365

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	12	25	$1,059
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	16	43	$809
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	20	$805

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$3	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	869	$1,512,231	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amanda Lynn Gillespie-Twardy, M.D.?

Tedicare shows public-source Medicare data for Amanda Lynn Gillespie-Twardy, M.D. (NPI 1417140559), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amanda Lynn Gillespie-Twardy, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amanda Lynn Gillespie-Twardy, M.D.?

Amanda Lynn Gillespie-Twardy, M.D. is linked to ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (billing NPI 1487621496) in the available physician profile data.

Does Amanda Lynn Gillespie-Twardy, M.D. have Open Payments data?

Amanda Lynn Gillespie-Twardy, M.D. has 870 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.